期刊文献+

DNA同源重组修复与乳腺癌的研究进展 被引量:7

Research progress of relationship between DNA homologous recombination repair and breast cancer
下载PDF
导出
摘要 双链断裂是真核细胞最严重的DNA损伤类型,主要依赖同源重组途径进行修复。BRCA1/2是该修复通路中的关键因子,以其为核心组成的BRCA肿瘤抑制因子网络中多种致病性突变均可损伤基因组完整性和稳定性,增高乳腺癌易感性。该文结合最新研究进展,对DNA同源重组修复网络中关键基因突变与乳腺癌易感性及个体化治疗策略进行综述,旨在促进相关突变携带者的乳腺癌早期预防、分子诊断和精准治疗。 Double-strand DNA breaks ( DSBs) are the most dele-terious events in eukaryotic cells , and there are two major path-ways for repairing them: homologous recombination ( HR ) and non-homologous DNA end joining ( NHEJ ) .BRCA1/2 proteins are key factors in HR repair pathway for DSBs and play an es-sential role in BRCA tumor suppressor network , which maintains genomic integrity and stability .Pathogenic mutations of core genes in this network may damage the DNA repair process and increase the risk of breast cancer .This review summarizes the current reports on the relationship between breast cancer suscep-tibility and mutations of the key factors in DNA HR repair asso-ciated tumor suppressor network , and aims at promoting the pre-vention, molecular diagnosis and precision treatment of the breast cancer patients with aforementioned mutations .
出处 《中国药理学通报》 CAS CSCD 北大核心 2016年第7期910-914,共5页 Chinese Pharmacological Bulletin
基金 国家自然科学青年基金项目(No 81402408) 国家科技支撑计划项目(No 2015BAI12B15)
关键词 DNA双链断裂 同源重组修复 乳腺肿瘤 易感基因 抑癌基因 BRCA 化疗 DNA double-strand DNA breaks homologous re-combination repair breast neoplasm susceptibility gene tumor suppressor gene BRCA chemotherapy
  • 相关文献

参考文献1

二级参考文献12

  • 1McGrogan B T,Gilmartin B, Carney D N, et al. Taxanes, microtubules and chemoresistant breast cancer[ J]. Biochim Biophys Acta, 2008,85(2) : 96 - 132.
  • 2Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents [ J ]. Ann Oncol, 2007, 18 ( Suppl 12) : xii15 -20.
  • 3Azambuja E, Durbecq V, Rosa D D, et al. HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer[ J]. Ann Orwol,2008,19(2) : 223 -32.
  • 4Jordan M A, Wilson L. Microtubules as a target for anticancer drugs[J]. Nat Rev Cancer, 2004,4(4) : 253 -65.
  • 5Pegram M D, Finn R S, Arzoo K, et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells [ J]. Oncogene, 1997,15 (5) : 537 - 47.
  • 6Yu D, Liu B, Tan M, et al. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to taxol via mdr-1- independent mechanisms [ J ]. Oncogene, 1996, 13 (6) : 1359 - 65.
  • 7Ciardiello F, Caputo R, Pomatico G, et al. Resistance to taxanes is induced by cerbB-2 overcxpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type Ⅰ protein kinase A [ J ]. lnt J Cancer, 2000,85(5) : 710 -5.
  • 8Gligorov J, Lotz J P. Preclinieal pharmacology of the taxanes : implications of the differences[ J]. Oncologist, 2004,9( Suppl 2 ) : 3 -8.
  • 9Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocareinoma cells[J]. Oncogene, 2003, 22(21): 3205-12.
  • 10O'Brien C, Caret G, Pandita A, et al. Functional genomics identities ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer [ J]. Cancer Res, 2008,68 ( 13 ) : 5380 - 9.

共引文献9

同被引文献41

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部